Maze Therapeutics (NASDAQ:MAZE) Given New $110.00 Price Target at HC Wainwright

Maze Therapeutics (NASDAQ:MAZE) had its price objective boosted by HC Wainwright from $60.00 to $110.00 in a research note released on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities analysts have also recently weighed in on MAZE. Wells Fargo & Company started coverage on Maze Therapeutics in a report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price target for the company. BTIG Research reaffirmed a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research note on Monday, March 9th. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Finally, Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $64.11.

Maze Therapeutics Price Performance

Shares of MAZE opened at $31.73 on Wednesday. Maze Therapeutics has a 1-year low of $6.71 and a 1-year high of $53.65. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of -1.52 and a beta of 4.47. The firm has a 50 day simple moving average of $45.98 and a 200-day simple moving average of $37.55.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share (EPS) for the quarter.

Insiders Place Their Bets

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction dated Thursday, January 29th. The stock was sold at an average price of $44.27, for a total value of $332,025.00. Following the completion of the sale, the insider owned 10,503 shares in the company, valued at $464,967.81. The trade was a 41.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Amy Bachrodt sold 5,000 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $46.04, for a total transaction of $230,200.00. Following the transaction, the senior vice president owned 12,965 shares in the company, valued at approximately $596,908.60. The trade was a 27.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 245,000 shares of company stock valued at $10,504,792.

Hedge Funds Weigh In On Maze Therapeutics

A number of large investors have recently bought and sold shares of the stock. Royal Bank of Canada boosted its holdings in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Maze Therapeutics during the 4th quarter valued at $39,000. Ameritas Investment Partners Inc. increased its holdings in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after buying an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Maze Therapeutics in the 4th quarter worth $43,000. Finally, Russell Investments Group Ltd. raised its position in shares of Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after buying an additional 1,725 shares during the period.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Topline Phase 2 HORIZON results showed meaningful proteinuria (uACR) reductions across a broad APOL1‑mediated kidney disease population, including a 61.8% mean uACR reduction in an FSGS subgroup and large reductions in non‑diabetic patients; company plans to advance MZE829 into a pivotal program. Globe Newswire: Positive Topline Data
• Positive Sentiment: Analysts reacted bullishly despite volatility — HC Wainwright raised its price target sharply (to $110) and BTIG reaffirmed a Buy with a $46 target, supporting upside expectations if pivotal data confirm benefit. Benzinga: Analyst Coverage
• Neutral Sentiment: Maze reported Q4 and full‑year 2025 results (EPS -$0.65) and highlighted a strong cash position (about $360M) with runway into 2028 — gives the company financial flexibility to fund pivotal development. Earnings Release
• Neutral Sentiment: Board strengthening: Neil Kumar (BridgeBio founder/CEO) was added to the board, which could add industry experience and credibility around development strategy. TipRanks: Board Addition
• Negative Sentiment: Despite positive data, the stock plunged and the company “lost nearly a third” of market value in heavy trading as some investors viewed the readout as mixed or chose to take profits, driving sharp intraday declines. BioSpace: Market Reaction
• Negative Sentiment: Insider sale: an executive exercised options and sold 15,000 shares (~$736K), an action that may have increased sell‑side pressure and contributed to the stock drop. Motley Fool: Insider Sale
• Negative Sentiment: Mixed media/analyst headlines amplified volatility — some outlets emphasize “best‑in‑class potential” while others focus on the sell‑off, increasing short‑term uncertainty and trading volume. FierceBiotech: Mixed Coverage

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.